Corporate Governance
For MEDICLIN, corporate governance means corporate management oriented towards a responsible and sustainable value creation. Our corporate governance report creates transparency about the corporate governance self-understanding of MEDICLIN.
Corporate Governance Declaration (Sec. 289a HGB)
We see the Corporate Governance Declaration as a chance to disclose the stability and sustainability of the corporate governance of MEDICLIN Aktiengesellschaft. We want to publish this in an area that is generally accessible to the public.
Management
Management Board
-
Volker Hippler
CEO
Tino Fritz
CFO
Supervisory Board
-
Dr. Jan Liersch
Chairman, Managing Director Broermann Holding GmbH
Hans Hilpert*
Vice Chairman, Sports Therapist
Michael Bock
Managing Director of REALKAPITAL Vermögensmanagement GmbH
Barbara Brosius
Former Vice Chairwoman und Managing Director of UBS Deutschland AG
Dr. Julianna Dannath-Schuh
Partner und Managing Director der MANRES AG
Walburga Erichsmeier*
Deputy District Manager at ver.di trade union for the district of Ostwestfalen-Lippe
Kai Hankeln
CEO of Asklepios Kliniken Gruppe and Managing Director of Asklepios Kliniken Management GmbH
Rainer Laufs
Independent Business Consultant
Thomas Müller*
District Manager at ver.di trade union for the district of Saar-Trier
Elke Schwan*
Masseurin und medizinische Bademeisterin
Frauke Schwedt*
Diplom-Psychologin / Psychologische Psychotherapeutin
Daniela Sternberg-Kinzel*
Head of patient management
Matthias H. Werner*
Social Pedagogue (BA)/Adventure Pedagogue
Dr. Thomas Witt*
Chief Physician
Cornelia Wolf
Head of Group division Audit and Risk Management of Asklepios Kliniken GmbH & CO. KGaA
* Employee representative on the Supervisory Board
Supervisory Board Committees
-
General and Personnel Committee
Dr. Jan Liersch (Chairman), Hans Hilpert (Vice Chairman), Rainer Laufs, Thomas Müller, Dr. Thomas Witt
Audit Committee
Michael Bock (Chairman), Walburga Erichsmeier, Matthias H. Werner, Cornelia Wolf
Meditation Committee pursuant to § 27 MitbestG
Dr. Jan Liersch (Chairman), Hans Hilpert (Vice Chairman), Frauke Schwedt, Cornelia Wolf
Nomination Committee
Dr. Jan Liersch (Chairman), Michael Bock, Cornelia Wolf
Directors' Dealings
Publication of Managers‘ Transactions pursuant to Art. 19 Market Abuse Regulation (MAR)
The reporting and disclosure duty applies to members of the Board of Management and of the Supervisory Board, and to persons closely associated with them. It also applies to legal entities, other companies, or organizations acting by order of or in the interests of the aforementioned persons. Any subsequent transactions once a total transaction volume of EUR 5,000.00 has been reached within a calendar year must be reported. The transactions of each person are to be considered separately.
We did not receive any notification of transactions.
